The CRISPR-Cas9 system delivered by these BNMs successfully knocked out the YTHDF1 gene in DCs, leading to CD8 + T cell-mediated tumor inhibition in MC38 tumor-bearing mouse models. Here, CD8A is linked to neoplasm.